Search
Close this search box.

Five things that make Azzad unique

Five things that make Azzad unique

At Azzad, we believe that an investment has moral as well as financial implications. “Do no mischief on the earth after it has been set in order; but call on Him with fear and longing (in your hearts) for the Mercy of Allah is (always) near to those who good.” (Surah Al-A’raf, Ayah 56) To invest in a company that engages in Islamically impermissible activities is harmful to the investor because s/he profits from haram activities through dividend or interest income. It is harmful to society as a whole because what we buy is an expression of our ethics and moral worldview. To support unjust, economically exploitative enterprises helps to perpetuate, either in practice or in spirit, actions that are corrosive to the soul and society. As such, we do not cut corners when it comes to Shariah compliance, embracing both the letter and the spirit of the law. Azzad’s adherence to internationally accepted guidelines for Islamic investing is unrivaled. The Accounting and Auditing Organization for Islamic Financial Institutions (AAOIFI) serves as the backbone of our Shariah compliance process. This means rigorous screening that involves data feeds on company business activities from two internationally known vendors, Thomson Reuters and MSCI.

Read More »

Investors say executive pay packages at pharma may incentivize drug pricing risks

In resolutions at five U.S. drug makers, investors request a review of compensation policies that may drive senior execs to ignore the long-term business risks of skyrocketing drug costs. Falls Church, Va., 12/14/17 – Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information about how well executive pay incentives mitigate long-term financial risks associated with mounting public concerns over the affordability of prescription medicines. The investors are all members of the Interfaith Center on Corporate Responsibility (ICCR), a shareholder coalition that has been engaging the pharma sector for decades on drug access and affordability. In the resolutions, the investors argue that an executive compensation incentive program reliant on revenue growth solely from drug price increases is a risky and unsustainable strategy. The resolution specifically requests a report on the extent to which risks related to public concern over drug pricing strategies are reflected in executive compensation policies, plans and programs. Read the full resolution text here.The five companies receiving the resolutions are Abbvie, Amgen, Biogen, Bristol Myers Squibb, and Eli Lilly. ICCR members also filed a separate but similar resolution at Pfizer and Vertex requesting a report on the business risks from rising pressure to contain U.S. prescription

Read More »

Azzad Asset Management

You are about to leave the Azzad website and enter a third-party website. We are not responsible for and cannot guarantee the accuracy of any information on a third-party website.

You will be redirected to

Click the link above to continue or CANCEL